The Guideline's Preferred Third Agent, Set Against His Own Gout History
Chlorthalidone is usually the textbook next step for hypertension like his. His own gout history is the specific, personal reason that textbook step isn't automatically the right one for him.
O.D., a 60-year-old man, has kept bees as a serious hobby for over a decade, tending hives across three properties and selling honey at a farmers market most weekends. He has hypertension poorly controlled on lisinopril and amlodipine at maximum doses, blood pressure averaging 156/94 on home monitoring over the past month despite documented medication adherence. He is not yet resistant by definition — that requires three agents including a diuretic — and the diuretic is exactly the step in question. He also has a history of gout, three confirmed flares over the past five years, most recently eight months ago, managed acutely with colchicine and maintained since on allopurinol, and a family history of gout on his father's side that he says makes him unusually attentive to anything that might trigger another flare.
The standard next step for hypertension not controlled on an ACE inhibitor and a calcium channel blocker is a thiazide-like diuretic, chlorthalidone specifically favored in current guidelines for its longer half-life and stronger outcomes evidence compared to hydrochlorothiazide. That default runs directly into his gout history: thiazide diuretics reduce renal uric acid excretion, raising serum urate and measurably increasing the risk of gout flares, a well-established class effect that makes the guideline's preferred third agent a real liability for a patient whose gout is already a known, recurring problem rather than a theoretical risk. Both existing agents are already at maximum dose, so the choice isn't between adding a thiazide and doing nothing — it's between accepting the guideline's default third agent despite his gout history, or moving an agent normally reserved for the fourth position up a step to avoid that specific interaction.
At the uncontrolled-hypertension follow-up
By the numbers he's a straightforward two-drug-failure case — not resistant hypertension in the formal sense, since that needs three drugs including a diuretic — and chlorthalidone is the standard next step — longer half-life and stronger outcomes evidence than hydrochlorothiazide, favored in current guidelines. I want to flag his gout history before we default to it, though, since thiazides reduce renal urate excretion and raising his risk here isn't hypothetical given three flares already on record.
Agreed that's a real, not theoretical, concern for him specifically. Spironolactone is the usual fourth-line agent in resistant hypertension algorithms and has genuinely strong evidence of its own — though I'd note that evidence comes from patients already on three drugs including a diuretic, which is not where he is, and it doesn't carry a gout-specific advantage so much as an absence of the thiazide's gout liability.
I'd reach for spironolactone anyway despite that, since it is consistently the most effective add-on in the resistant-hypertension algorithms, and I'm comfortable using it one position earlier than those trials tested it in order to keep a thiazide out of a man with three documented flares. His allopurinol maintenance also means a thiazide stays available later if this doesn't hold. Starting spironolactone 25 mg daily, with potassium and renal function rechecked in two weeks given the ACE inhibitor he's already on.
Spironolactone 25 mg daily added to his existing maximized lisinopril and amlodipine. Potassium and renal function rechecked at 2 weeks given the combination with an ACE inhibitor.
Agreed without real disagreement once the gout-specific concern was named directly; the standing note for future reference:
If spironolactone proves inadequate or intolerable, chlorthalidone would remain available as a later option given his stable allopurinol maintenance, rather than being permanently excluded — the gout history changed which agent came first, not which agents remain available at all.